Edition:
India

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

11.52EUR
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
€11.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
286,624
52-wk High
€15.24
52-wk Low
€8.38

Latest Key Developments (Source: Significant Developments)

Medigene says 9M immunotherapy revenue 3.4 mln eur
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Medigene :Says confirms its financial guidance for 2017.Says 9M revenue from core business immunotherapies (bluebird bio partnership) of eur 3.435 million.Says 9M total revenue eur 7.176 million (9M 2016: eur 7.052 million).Says 9M EBITDA loss increased as planned to eur 10.143 million (9M 2016: eur 9.095 million).  Full Article

bluebird bio and Medigene establish strategic T cell receptor alliance
Thursday, 29 Sep 2016 

Medigene AG : bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy . Medigene will be responsible for generation and delivery of TCRs using its TCR isolation and characterization platform . Medigene will receive an upfront payment of $15 million .Medigene will receive research and development funding for all work performed in the collaboration and is eligible for tiered royalty payments on net sales up to a double-digit percentage.  Full Article

Medigene H1 total revenue up 62 pct at 5.5 mln euros
Friday, 5 Aug 2016 

Medigene AG : H1 total revenue increased by 62 pct to 5.470 million euros (6M 2015: 3.372 million euros) . H1 cash and cash equivalents and time deposits increased by 4 pct to 48.672 million euros (12/31/2015: 46.759 million euros) . Confirms its financial guidance for fiscal year 2016 . H1 research and development expenses increased by 23 pct to 5.079 million euros (6M 2015: 4.117 million euros) .H1 EBITDA loss reduced by 6 pct to 4.011 million euros (6M 2015: 4.251 million euros).  Full Article

Medigene: grant of US patent for method for identification of CD4+ t cell antigens
Monday, 25 Jul 2016 

Medigene AG : Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens . Patent covers a rapid and efficient method for identifying tumor-specific antigens .Expected to facilitate use of neoantigens in personalized T-cell therapies.  Full Article

Medigene joins Max Delbrück Centre and Charité for first clinical TCR study in Germany
Wednesday, 29 Jun 2016 

Medigene AG :Enters into a cooperation agreement with Max Delbrück Centre for Molecular Medicine in Helmholtz Association (MDC) and the Charité - Universitätsmedizin Berlin (Charité).  Full Article

Medigene commissions EUFETS for cell production process for first own TCR studies
Wednesday, 18 May 2016 

Medigene AG : Commissions EUFETS for cell production process for first own TCR studies .EUFETS will set up cell production together with Medigene for supplying company's planned phase I/II TCR studies.  Full Article

Medigene Q1 total revenue up at 3.909 mln euros
Thursday, 12 May 2016 

Medigene AG : Q1 increase in total revenue by 132 pct to 3.909 million euros (3m 2015: 1.686 mln euros) . Q1 EBITDA loss reduced by 54 pct to 939,000 euros (3m 2015: 2.042 million euros) . Q1 increase in research and development expenses for immunotherapies by 64 pct to 1.907 million euros (3m 2015: 1.166 mln euros) .Confirmation of financial guidance 2016.  Full Article

Medigene announces issuance and number of new shares
Tuesday, 10 May 2016 

Medigene AG : Medigene announces issuance and number of new shares to settle milestone payment for start of phase II trial with dc vaccines . Milestone payment in value of approx 3.2 million euros ($3.65 million) announced on April 1 will be settled through issuance of 392,875 new shares from authorized capital as part of capital increase through contributions in kind .Thereby, company will increase its share capital of 19,688,960.00 euros up to 20,081,835.00 euros.  Full Article

Medigene sells partial stake in Immunocore
Monday, 4 Apr 2016 

Medigene AG:Sells partial stake in Immunocore.Sold 50 pct of its' stake in private biotech company Immunocore Ltd., UK, for approximately 4.9 million pounds (about 6.1 million euros).  Full Article

Medigene announces start of phase II trial with DC vaccines
Friday, 1 Apr 2016 

Medigene AG:Announces start of phase II trial with DC vaccines and upcoming milestone payment.Milestone payment of about 3.2 million euros to be made by Medigene to former contributing shareholders of Medigene Immunotherapies within next 5 months.  Full Article

BRIEF-Medigene to issue new shares to settle Trianta milestone payment

* Announces issuance and number of new shares to settle last Trianta milestone payment